Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548231 | 0.80 | POLB (0.69) | MEN1NPC1TP53RAB9AKMT2A | |
| SCHEMBL549145 | 0.72 | ALDH1A1 (0.43) | MEN1NPC1TP53RAB9AKMT2A | |
| SCHEMBL14144370 | 0.71 | CNR1 (0.44) | CNR2 | |
| SCHEMBL31324296 | 0.69 | SMN1; SMN2 (0.52) | MEN1NPC1TP53RAB9AKMT2A | |
| SCHEMBL548988 | 0.69 | TP53 (0.44) | TP53POLBL3MBTL1 | |
| SCHEMBL10608500 | 0.69 | KMT2A (0.49) | MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL28463382 | 0.68 | L3MBTL1 (0.60) | MEN1NPC1KMT2APOLBL3MBTL1 | |
| SCHEMBL549152 | 0.68 | GABRA2 (0.58) | MEN1NPC1TP53RAB9AKMT2A | |
| SCHEMBL548339 | 0.68 | POLB (0.62) | MEN1NPC1TP53RAB9AKMT2A | |
| SCHEMBL10768639 | 0.67 | LMNA (0.42) | MEN1KMT2AL3MBTL1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2010-09-02 | — | — | US | claimed |
| US-8110588-B2 | 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2012-02-07 | — | — | US | disclosed |
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA3, CHRNB3, CHRNA5 | MEN1 4048/4885NPC1 2998/4885TP53 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.